Anika Therapeutics
ANIK

$27.90

1.45%

Market Cap: 414M

About: Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.

Employees: 357

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 4 analysts

0

News positive %

of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

193% more call options, than puts

Call options by funds: $469K | Put options by funds: $160K

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

13% more capital invested

Capital invested by funds: $300M [Q4 2023] → $340M (+$40M) [Q1 2024]

2% more funds holding

Funds holding: 116 [Q4 2023] → 118 (+2) [Q1 2024]

5% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 41

0.99% more ownership

Funds ownership: 90.5% [Q4 2023] → 91.49% (+0.99%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 3 (+0) [Q1 2024]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$22

21%

downside

Avg. target

$30

8%

upside

High target

$37

33%

upside

4 analyst ratings

2 positive

50%

2 neutral

50%

0 negative

0%

Stephens & Co. George Sellers	14%downside $24	Equal-Weight Reiterated	29 May 2024
Barrington Research Michael Petusky	33%upside $37	Outperform Maintained	9 May 2024
Barrington Research Michael Petusky	33%upside $37	Outperform Maintained	14 Mar 2024
Stephens & Co. George Sellers	21%downside $22	Equal-Weight Reiterated	14 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ANIK published over the past 30 days

Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024

BEDFORD, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2024 financial results after the close of the market on Thursday, August 8, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on July 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.85, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs

Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolio

Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs

Orthopedic Regenerative Surgical Products Market Size to Reach USD 6.6 Billion By 2033, at 4.4 CAGR: Insights by Dimension Market Research

Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments

Orthopedic Regenerative Surgical Products Market Size to Reach USD 6.6 Billion By 2033, at 4.4 CAGR: Insights by Dimension Market Research

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on June 3, 2024, Anika granted: (i) non-statutory stock options (“Options”) covering 96,525 shares of common stock at a per share exercise price of $29.35, which equaled 110% of the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, and (ii) restricted stock units (“RSUs”) covering 38,520 shares of common stock, to Stephen Griffin, the Company's recently appointed Executive Vice President, Chief Financial Officer and Treasurer. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), were made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Enters into Cooperation Agreement with Caligan Partners

Appoints Joseph Capper and William Jellison to Board of Directors Announces New $40 Million Share Repurchase Program

Anika Enters into Cooperation Agreement with Caligan Partners

Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript

Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2024 Earnings Conference Call May 8, 2024 5:30 PM ET Company Participants Mark Namaroff - Vice President of Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michael Levitz - Executive Vice President and Chief Financial Officer Conference Call Participants George Sellers - Stephens Inc. James Sidoti - Sidoti & Company, LLC Mike Petusky - Barrington Research Operator Good evening, ladies and gentlemen, and welcome to Anika's First Quarter 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.

Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript

Anika Announces CFO Transition

Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024 Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024

Anika Announces CFO Transition

Anika Reports First Quarter 2024 Financial Results

Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the midpoint BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2024.

Anika Reports First Quarter 2024 Financial Results

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on May 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 3,800 shares of common stock at a per share exercise price of $26.49, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings